2022 Q3 Form 10-K Financial Statement

#000118518522001017 Filed on August 25, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022
Revenue $6.045M $6.160M $22.66M
YoY Change 9.89% 1.66% 17.47%
Cost Of Revenue $3.003M $3.134M $11.12M
YoY Change 15.29% -0.75% 15.34%
Gross Profit $3.042M $3.026M $11.54M
YoY Change 5.04% 4.28% 19.61%
Gross Profit Margin 50.33% 49.12% 50.92%
Selling, General & Admin $3.202M $2.976M $12.42M
YoY Change 10.58% -3.5% 14.96%
% of Gross Profit 105.26% 98.35% 107.61%
Research & Development $0.00 $17.36K
YoY Change -100.0% -53.23%
% of Gross Profit 0.0% 0.15%
Depreciation & Amortization $236.9K $218.4K $753.7K
YoY Change 33.63% 25.33% 9.99%
% of Gross Profit 7.79% 7.22% 6.53%
Operating Expenses $3.202M $2.976M $12.42M
YoY Change 10.58% -3.5% -6.64%
Operating Profit -$160.1K $49.90K -$877.9K
YoY Change -35678.89% -127.37% -75.96%
Interest Expense $766.7K -$845.7K $2.150M
YoY Change -283.16% -40.44% -41.22%
% of Operating Profit -1694.81%
Other Income/Expense, Net -$652.9K $479.0K
YoY Change -186.43% -104.91%
Pretax Income -$813.0K -$273.6K -$398.9K
YoY Change -207.55% -96.44% -97.02%
Income Tax $519.1K $1.248M $2.041M
% Of Pretax Income
Net Earnings -$1.148M -$1.433M -$2.343M
YoY Change -368.59% -85.93% -85.25%
Net Earnings / Revenue -19.0% -23.26% -10.34%
Basic Earnings Per Share -$0.04 -$0.02
Diluted Earnings Per Share -$0.04 -$11.18K -$0.02
COMMON SHARES
Basic Shares Outstanding 128.2M shares 128.1M shares
Diluted Shares Outstanding 32.05M shares 128.1M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $592.0K $2.552M $2.552M
YoY Change -69.81% 53.24% 53.24%
Cash & Equivalents $592.0K $2.552M $2.552M
Short-Term Investments
Other Short-Term Assets $418.5K $295.9K $295.9K
YoY Change 61.22% 12.79% 17.26%
Inventory $4.216M $3.418M $3.418M
Prepaid Expenses $418.4K $295.9K
Receivables $739.2K $618.2K $618.2K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $5.966M $6.884M $6.884M
YoY Change 33.23% 79.23% 79.23%
LONG-TERM ASSETS
Property, Plant & Equipment $4.222M $4.342M $6.497M
YoY Change -24.61% 24.94% 13.47%
Goodwill $557.9K $557.9K
YoY Change 0.0%
Intangibles $1.162M $1.190M
YoY Change -8.8%
Long-Term Investments $1.040M $469.6K $469.6K
YoY Change
Other Assets $219.0K $229.5K $229.5K
YoY Change 30.78% 37.05% 37.05%
Total Long-Term Assets $9.316M $8.944M $8.944M
YoY Change 22.55% 15.32% 15.32%
TOTAL ASSETS
Total Short-Term Assets $5.966M $6.884M $6.884M
Total Long-Term Assets $9.316M $8.944M $8.944M
Total Assets $15.28M $15.83M $15.83M
YoY Change 26.51% 36.48% 36.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.671M $1.414M $1.414M
YoY Change 124.0% 83.21% 83.21%
Accrued Expenses $1.390M $1.633M $1.633M
YoY Change 16.58% 17.3% 17.3%
Deferred Revenue
YoY Change
Short-Term Debt $1.153M $1.013M $1.013M
YoY Change
Long-Term Debt Due $19.52M $19.52M $19.52M
YoY Change 5449.77% 5806.39% 5806.39%
Total Short-Term Liabilities $28.79M $28.11M $28.11M
YoY Change 463.48% 463.99% 463.99%
LONG-TERM LIABILITIES
Long-Term Debt $3.146M $2.971M $2.971M
YoY Change -83.83% -84.94% -84.94%
Other Long-Term Liabilities $1.829M $1.894M $1.894M
YoY Change -4.25% -4.32% -4.32%
Total Long-Term Liabilities $4.974M $4.865M $4.865M
YoY Change -76.71% -77.59% -77.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $28.79M $28.11M $28.11M
Total Long-Term Liabilities $4.974M $4.865M $4.865M
Total Liabilities $33.76M $32.98M $32.88M
YoY Change 27.56% 23.54% 23.17%
SHAREHOLDERS EQUITY
Retained Earnings -$96.23M -$95.08M
YoY Change 2.53%
Common Stock $3.206K $12.82K
YoY Change 0.78%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$18.20M -$17.05M -$17.05M
YoY Change
Total Liabilities & Shareholders Equity $15.28M $15.83M $15.83M
YoY Change 26.51% 36.48% 36.48%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022
OPERATING ACTIVITIES
Net Income -$1.148M -$1.433M -$2.343M
YoY Change -368.59% -85.93% -85.25%
Depreciation, Depletion And Amortization $236.9K $218.4K $753.7K
YoY Change 33.63% 25.33% 9.99%
Cash From Operating Activities -$1.462M -$600.3K -$3.158M
YoY Change 86.15% 25.46% 24.56%
INVESTING ACTIVITIES
Capital Expenditures $88.23K -$938.9K $1.105M
YoY Change -194.89% 964.91% 310.04%
Acquisitions
YoY Change
Other Investing Activities -$457.1K -$39.01K $2.097M
YoY Change -138.93% 35.79%
Cash From Investing Activities -$545.3K -$977.9K $992.3K
YoY Change -150.44% 1009.03% -22.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $47.25K 675.5K $3.052M
YoY Change
NET CHANGE
Cash From Operating Activities -$1.462M -600.3K -$3.158M
Cash From Investing Activities -$545.3K -977.9K $992.3K
Cash From Financing Activities $47.25K 675.5K $3.052M
Net Change In Cash -$1.960M -902.7K $886.6K
YoY Change -762.5% 59.3% -170.35%
FREE CASH FLOW
Cash From Operating Activities -$1.462M -$600.3K -$3.158M
Capital Expenditures $88.23K -$938.9K $1.105M
Free Cash Flow -$1.550M $338.6K -$4.262M
YoY Change 123.89% -186.75% 51.98%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-05-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--05-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
000-55546
CY2022 dei Entity Registrant Name
EntityRegistrantName
CLS HOLDINGS USA, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-1352286
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
11767 South Dixie Highway, Suite 115
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Miami
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
FL
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
33156
CY2022 dei City Area Code
CityAreaCode
888
CY2022 dei Local Phone Number
LocalPhoneNumber
438-9132
CY2022 dei Security12b Title
Security12bTitle
N/A
CY2022 dei Trading Symbol
TradingSymbol
N/A
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Public Float
EntityPublicFloat
12503655 usd
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
128208082 shares
CY2022 dei Auditor Firm
AuditorFirmId
2738
CY2022 dei Auditor Name
AuditorName
M&K CPAS, PLLC
CY2022 dei Auditor Location
AuditorLocation
Houston, TX
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2551859 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1665263 usd
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
618227 usd
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
684935 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
3417602 usd
CY2021Q2 us-gaap Inventory Net
InventoryNet
1228052 usd
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
295869 usd
CY2021Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
262313 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
6883557 usd
CY2021Q2 us-gaap Assets Current
AssetsCurrent
3840563 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2073449 usd
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1434614 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4342434 usd
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3475668 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2154517 usd
CY2021Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2250009 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
473308 usd
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
358403 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1190285 usd
CY2021Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1305190 usd
CY2022Q2 us-gaap Goodwill
Goodwill
557896 usd
CY2021Q2 us-gaap Goodwill
Goodwill
557896 usd
CY2022Q2 us-gaap Other Long Term Investments
OtherLongTermInvestments
469575 usd
CY2021Q2 us-gaap Other Long Term Investments
OtherLongTermInvestments
0 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
229500 usd
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
167455 usd
CY2022Q2 us-gaap Assets
Assets
15827764 usd
CY2021Q2 us-gaap Assets
Assets
11596781 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2317898 usd
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1608625 usd
CY2022Q2 us-gaap Interest Payable Current
InterestPayableCurrent
419206 usd
CY2021Q2 us-gaap Interest Payable Current
InterestPayableCurrent
267945 usd
CY2022Q2 us-gaap Loans Payable Current
LoansPayableCurrent
1013073 usd
CY2021Q2 us-gaap Loans Payable Current
LoansPayableCurrent
0 usd
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
71813 usd
CY2021Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
309597 usd
CY2021Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
287125 usd
CY2022Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4531782 usd
CY2021Q2 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2490295 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
0 usd
CY2021Q2 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
35496 usd
CY2022Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
19448821 usd
CY2021Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
330495 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
28112190 usd
CY2021Q2 us-gaap Liabilities Current
LiabilitiesCurrent
4984485 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1893810 usd
CY2021Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1979294 usd
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
277180 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
1681434 usd
CY2021Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
0 usd
CY2022Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
2693566 usd
CY2021Q2 us-gaap Long Term Notes Payable
LongTermNotesPayable
0 usd
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
0 usd
CY2021Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
0 usd
CY2022Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
0 usd
CY2021Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
19729822 usd
CY2022Q2 us-gaap Liabilities
Liabilities
32976746 usd
CY2021Q2 us-gaap Liabilities
Liabilities
26693601 usd
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2021Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0 usd
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2021Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2021Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2021Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
128208082 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
128208082 shares
CY2021Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
127221416 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
127221416 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
12822 usd
CY2021Q2 us-gaap Common Stock Value
CommonStockValue
12723 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
77945132 usd
CY2021Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
77561393 usd
CY2022Q2 clsh Stock Payable
StockPayable
70092 usd
CY2021Q2 clsh Stock Payable
StockPayable
65702 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95079817 usd
CY2021Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-92736638 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-17051771 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-15096820 usd
CY2022Q2 us-gaap Minority Interest
MinorityInterest
-97211 usd
CY2021Q2 us-gaap Minority Interest
MinorityInterest
0 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-17148982 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-15096820 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
15827764 usd
CY2021Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11596781 usd
CY2022 us-gaap Revenues
Revenues
22662895 usd
CY2021 us-gaap Revenues
Revenues
19292087 usd
CY2022 us-gaap Cost Of Revenue
CostOfRevenue
11123857 usd
CY2021 us-gaap Cost Of Revenue
CostOfRevenue
9644761 usd
CY2022 us-gaap Gross Profit
GrossProfit
11539038 usd
CY2021 us-gaap Gross Profit
GrossProfit
9647326 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12416893 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10800944 usd
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2498706 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
12416893 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
13299650 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-877855 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-3652324 usd
CY2022 us-gaap Interest Expense
InterestExpense
2149729 usd
CY2021 us-gaap Interest Expense
InterestExpense
3657105 usd
CY2022 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
0 usd
CY2021 us-gaap Gain Loss On Sale Of Other Assets
GainLossOnSaleOfOtherAssets
14889 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6105679 usd
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-112139 usd
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 usd
CY2022 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
2740820 usd
CY2021 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
478952 usd
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9747895 usd
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-398903 usd
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13400219 usd
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2041487 usd
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2490295 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-2440390 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-15890514 usd
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-97211 usd
CY2021 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
0 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-2343179 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-15890514 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128128975 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
126664839 shares
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128128975 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
126664839 shares
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-5395548 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Other Longterm Incentive Plans Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
-25750 usd
CY2021 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
28500 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6105679 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-15890514 usd
CY2021Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-15096820 usd
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
281000 usd
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
8780 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
98448 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-2440390 usd
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-17148982 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-2440390 usd
CY2021 us-gaap Profit Loss
ProfitLoss
-15890514 usd
CY2022 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6105679 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
0 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
-25750 usd
CY2022 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
0 usd
CY2021 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
14889 usd
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-112139 usd
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 usd
CY2022 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
327509 usd
CY2021 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
2203234 usd
CY2022 clsh Fair Value Of Shares Vested By Officers
FairValueOfSharesVestedByOfficers
8780 usd
CY2021 clsh Fair Value Of Shares Vested By Officers
FairValueOfSharesVestedByOfficers
109313 usd
CY2022 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
2740820 usd
CY2021 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
0 usd
CY2022 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 usd
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2498706 usd
CY2022 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
753740 usd
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
685292 usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
79847 usd
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
15798 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-64361 usd
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
539324 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
111056 usd
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
28221 usd
CY2022 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2189550 usd
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
652810 usd
CY2022 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
0 usd
CY2021 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-2500 usd
CY2022 us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
-324904 usd
CY2021 us-gaap Increase Decrease In Operating Assets
IncreaseDecreaseInOperatingAssets
-341035 usd
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
709273 usd
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
435742 usd
CY2022 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
235425 usd
CY2021 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
258113 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
0 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-150000 usd
CY2022 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
2041487 usd
CY2021 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
2490295 usd
CY2022 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-40895 usd
CY2021 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0 usd
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-292424 usd
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-379358 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3157670 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2535159 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1104806 usd
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
269437 usd
CY2022 us-gaap Payments For Construction In Process
PaymentsForConstructionInProcess
62045 usd
CY2021 us-gaap Payments For Construction In Process
PaymentsForConstructionInProcess
0 usd
CY2022 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
581714 usd
CY2021 us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
0 usd
CY2022 us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
2740820 usd
CY2021 us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
1544291 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
992255 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1274854 usd
CY2022 us-gaap Proceeds From Loans
ProceedsFromLoans
2322875 usd
CY2021 us-gaap Proceeds From Loans
ProceedsFromLoans
0 usd
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
1393966 usd
CY2021 us-gaap Repayments Of Debt
RepaymentsOfDebt
0 usd
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
10907 usd
CY2022 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
2500000 usd
CY2021 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
0 usd
CY2022 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
365991 usd
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3052011 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
886596 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1260305 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1665263 usd
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2925568 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2551859 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1665263 usd
CY2022 us-gaap Interest Paid Capitalized
InterestPaidCapitalized
1656774 usd
CY2021 us-gaap Interest Paid Capitalized
InterestPaidCapitalized
943817 usd
CY2022 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
0 usd
CY2022 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
0 usd
CY2021 us-gaap Interest Costs Capitalized
InterestCostsCapitalized
212601 usd
CY2022 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
281000 usd
CY2021 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0 usd
CY2022 us-gaap Stock Issued1
StockIssued1
0 usd
CY2021 us-gaap Stock Issued1
StockIssued1
230470 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
229412 usd
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
400795 usd
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0 usd
CY2022 clsh Original Issue Discount On Notes Payable
OriginalIssueDiscountOnNotesPayable
1875000 usd
CY2021 clsh Original Issue Discount On Notes Payable
OriginalIssueDiscountOnNotesPayable
0 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
98448 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
0 usd
CY2022 us-gaap Other Significant Noncash Transaction Value Of Consideration Received1
OtherSignificantNoncashTransactionValueOfConsiderationReceived1
0 usd
CY2021 us-gaap Other Significant Noncash Transaction Value Of Consideration Received1
OtherSignificantNoncashTransactionValueOfConsiderationReceived1
1172726 usd
CY2022 us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE 1</b> –<b> BUSINESS ORGANIZATION AND NATURE OF OPERATIONS</b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">CLS Holdings USA, Inc. (the “Company”) was originally incorporated as Adelt Design, Inc. (“Adelt”) on March 31, 2011 to manufacture and market carpet binding art. Production and marketing of carpet binding art never commenced.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On November 12, 2014, CLS Labs acquired 10,000,000 shares, or 55.6%, of the outstanding shares of common stock of Adelt from its founder, Larry Adelt. On that date, Jeffrey Binder, the Chairman, President and Chief Executive Officer of CLS Labs, was appointed Chairman, President and Chief Executive Officer of the Company. On November 20, 2014, Adelt adopted amended and restated articles of incorporation, thereby changing its name to CLS Holdings USA, Inc. Effective December 10, 2014, the Company effected a reverse stock split of its issued and outstanding common stock at a ratio of 1-for-0.625 (the “Reverse Split”), wherein 0.625 shares of the Company’s common stock were issued in exchange for each share of common stock issued and outstanding. As a result, 6,250,000 shares of the Company’s common stock were issued to CLS Labs in exchange for the 10,000,000 shares that it owned by virtue of the above-referenced purchase from Larry Adelt.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On April 29, 2015, the Company, CLS Labs and CLS Merger Inc., a Nevada corporation and wholly owned subsidiary of CLS Holdings (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) and completed a merger, whereby CLS Merger Inc. merged with and into CLS Labs, with CLS Labs remaining as the surviving entity (the “Merger”). Upon the consummation of the Merger, the shares of the common stock of CLS Holdings owned by CLS Labs were extinguished and the former stockholders of CLS Labs were issued an aggregate of 15,000,000 (post Reverse Split) shares of common stock in CLS Holdings in exchange for their shares of common stock in CLS Labs. As a result of the Merger, the Company acquired the business of CLS Labs and abandoned its previous business.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company has been issued a U.S. patent with respect to its proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into concentrates such as oils, waxes, edibles and shatter. These concentrates may be ingested in a number of ways, including through vaporization via electronic cigarettes (“e-cigarettes”), and used for a variety of pharmaceutical and other purposes. Internal testing of this extraction method and conversion process has revealed that it produces a cleaner, higher quality product and a significantly higher yield than the cannabinoid extraction processes currently existing in the marketplace. The Company has not commercialized its patented proprietary process or otherwise earned any revenues from it. The Company plans to generate revenues through licensing, fee-for-service and joint venture arrangements related to its patented proprietary method of extracting cannabinoids from cannabis plants and converting the resulting cannabinoid extracts into saleable concentrates.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On December 4, 2017, the Company and Alternative Solutions, entered into a Membership Interest Purchase Agreement (the “Acquisition Agreement”), as amended, for the Company to acquire the Oasis LLCs from Alternative Solutions. Pursuant to the Acquisition Agreement, the Company initially contemplated acquiring all of the membership interests in the Oasis LLCs from Alternative Solutions. Just prior to closing, the parties agreed that the Company would instead acquire all of the membership interests in Alternative Solutions, the parent of the Oasis LLCs, from its members, and the membership interests in the Oasis LLCs owned by members other than Alternative Solutions.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pursuant to the Acquisition Agreement, the Company paid a non-refundable deposit of $250,000 upon signing, which was followed by an additional payment of $1,800,000 paid in February 2018, for an initial 10% of each of the Oasis LLCs. At that time, the Company applied for regulatory approval to own an interest in the Oasis LLCs, which approval was received. On June 27, 2018, the Company made the payments to indirectly acquire the remaining 90% of the Oasis LLCs, which were equal to cash in the amount of $5,995,543, a $4.0 million promissory note due in December 2019 (the “Oasis Note”), and 22,058,823 shares of its common stock (the “Purchase Price Shares”) (collectively, the “Closing Consideration”). The cash payment of $5,995,543 was less than the $6,200,000 payment originally contemplated because the Company assumed an additional $204,457 of liabilities. The Company used the proceeds of a Canadian private securities offering to fund the cash portion of the Closing Consideration. The Company then applied for regulatory approval to own the additional 90% in membership interests in the Oasis LLCs, which it received on December 12, 2018. The Company received final regulatory approval to own its interest in the Oasis LLCs through Alternative Solutions under the revised structure of the transaction on April 26, 2022.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On October 31, 2018, the Company, CLS Massachusetts, Inc., a Massachusetts corporation and a wholly-owned subsidiary of the Company (“CLS Massachusetts”), and In Good Health, Inc., a Massachusetts corporation (“IGH”), entered into an Option Agreement (the “IGH Option Agreement”). Under the terms of the IGH Option Agreement, CLS Massachusetts had an exclusive option to acquire all of the outstanding capital stock of IGH (the “IGH Option”) during the period beginning on the earlier of the date that is one year after the effective date of the conversion and December 1, 2019 and ending on the date that was 60 days after such date. If CLS Massachusetts exercised the IGH Option, the Company, a wholly-owned subsidiary of the Company and IGH would enter into a merger agreement (the form of which had been agreed to by the parties) (the “IGH Merger Agreement”). At the effective time of the merger contemplated by the IGH Merger Agreement, CLS Massachusetts would pay a purchase price of $47,500,000, subject to reduction as provided in the IGH Merger Agreement, payable as follows: $35 million in cash, $7.5 million in the form of a five-year promissory note, and $5 million in the form of restricted common stock of the Company, plus $2.5 million as consideration for a non-competition agreement with IGH’s President, payable in the form of a five-year promissory note. IGH and certain IGH stockholders holding sufficient aggregate voting power to approve the transactions contemplated by the IGH Merger Agreement entered into agreements pursuant to which such stockholders, among other things, agreed to vote in favor of such transactions. On October 31, 2018, as consideration for the IGH Option, the Company made a loan to IGH, in the principal amount of $5,000,000, subject to the terms and conditions set forth in that certain loan agreement, dated as of October 31, 2018 between IGH as the borrower and the Company as the lender. The loan was evidenced by a secured promissory note of IGH, which bore interest at the rate of 6% per annum and was to mature on October 31, 2021. To secure the obligations of IGH to the Company under the loan agreement and the promissory note, the Company and IGH entered into a security agreement dated as of October 31, 2018, pursuant to which IGH granted to the Company a first priority lien on and security interest in all personal property of IGH. If the Company did not exercise the Option on or prior to the date that was 30 days following the end of the option period, the loan amount would be reduced to $2,500,000 as a break-up fee, subject to certain exceptions set forth in the IGH Option Agreement. On August 26, 2019, the parties amended the IGH Option Agreement to, among other things, delay closing until January 2020. By letter agreement dated January 31, 2020, the Company, CLS Massachusetts and IGH extended the IGH Option Agreement to February 4, 2020. On February 4, 2020, CLS Massachusetts exercised the IGH Option and IGH subsequently asserted that CLS Massachusetts’ exercise was invalid. By letter dated February 26, 2020, the Company informed IGH that as a result of its breaches of the IGH Option, which remained uncured, an event of default had occurred under the IGH Note. The Company advised IGH that it was electing to cause the IGH Note to bear interest at the default rate of 15% per annum effective February 26, 2020 and to accelerate all amounts due under the IGH Note. On February 27, 2020, IGH informed CLS Massachusetts that it did not plan to make further payments under the IGH Note on the theory that the break-up excused additional payments. This dispute, including whether IGH breached the IGH Option and whether CLS was entitled to collect default interest, was in litigation. During the twelve months ended May 31, 2021, the Company impaired the remaining amounts due under the IGH Note in the amount of $2,498,706, which included $2,497,884 in principal and $822 in accrued interest.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On June 14, 2021, the parties to the IGH lawsuit entered into a confidential settlement agreement to resolve the action and a secured promissory note dated and executed by IGH in favor of the Company effective on June 11, 2021 (the “IGH Settlement Note”). Pursuant to the IGH Settlement Note, IGH shall pay the Company $3,000,000, $500,000 of which was paid on or before June 21, 2021. A second payment of $500,000 was paid on or before July 12, 2021. The remaining $2,000,000 and accrued interest is being paid in 12 equal monthly installments beginning on August 12, 2021, pursuant to the terms of the promissory note. During the year ended May 31, 2022, the Company received $2,740,820 under the IGH Settlement Note, which includes $2,666,670 in principal and $74,150 in accrued interest. As of May 31, 2022, the amount due under the IGH Settlement Note was $166,667. The Company records amounts paid under the IGH Settlement Note as gains when payments are received.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On October 20, 2021, the Company entered into a management services agreement (the “Quinn River Joint Venture Agreement”) through its 50% owned subsidiary, Kealii Okamalu, LLC (“Kealii Okamalu”), with CSI Health MCD LLC (“CSI”) and a commission established by the authority of the Tribal Council of the Fort McDermitt Paiute and Shoshone Tribe (the “Tribe”). The purpose of the Quinn River Joint Venture Agreement is to establish a business (the “Quinn River Joint Venture”) to grow, cultivate, process and sell cannabis and related products. The Quinn River Joint Venture Agreement has a term of 10 years plus a 10 year renewal term from the date the first cannabis crop produced is harvested and sold. Pursuant to the Quinn River Joint Venture Agreement, Kealii Okamalu expects to lease approximately 20-30 acres of the Tribe’s land located along the Quinn River at a cost of $3,500 per quarter and manage the design, finance and construction of a cannabis cultivation facility on such tribal lands (the “Cultivation Facility”). Kealii Okamalu will also manage the ongoing operations of the Cultivation Facility and related business, including, but not limited to, cultivation of cannabis crops, personnel staffing, product packaging, testing, marketing and sales. Packaged products will be branded as “Quinn River Farms.” The Company will provide 10,000 square feet of warehouse space at its Las Vegas facility, and will have preferred vendor status including the right to purchase cannabis flower and the business’s cannabis trim at favorable prices. Kealii Okamalu is expected to contribute $6 million towards the construction of the Cultivation Facility and the working capital for the Quinn River Joint Venture. This amount will be repaid from a portion of the net income of the Quinn River Joint Venture otherwise payable to CSI and the Tribe at the rate of $750,000 per quarter for eight quarters. Kealii Okamalu will receive one-third of the net profits of the Quinn River Joint Venture.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On January 4, 2018, the former Attorney General, Jeff Sessions, rescinded the memorandum issued by former Deputy Attorney General James Cole on August 29, 2013 (as amended on February 14, 2014, the “Cole Memo”), the Cole Banking Memorandum, and all other related Obama-era DOJ cannabis enforcement guidance. While the rescission did not change federal law, as the Cole Memo and other DOJ guidance documents were not themselves laws, the rescission removed the DOJ’s formal policy that state-regulated cannabis businesses in compliance with the Cole Memo guidelines should not be a prosecutorial priority. Notably, former Attorney General Sessions’ rescission of the Cole Memo has not affected the status of the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) memorandum issued by the Department of Treasury, which remains in effect. This memorandum outlines Bank Secrecy Act-compliant pathways for financial institutions to service state-sanctioned cannabis businesses, which echoed the enforcement priorities outlined in the Cole Memo. In addition to his rescission of the Cole Memo, Attorney General Sessions issued a one-page memorandum known as the “Sessions Memorandum”. The Sessions Memorandum explains the DOJ’s rationale for rescinding all past DOJ cannabis enforcement guidance, claiming that Obama-era enforcement policies are “unnecessary” due to existing general enforcement guidance adopted in the 1980s, in chapter 9.27.230 of the U.A. Attorneys’ Manual (“USAM”). The USAM enforcement priorities, like those of the Cole Memo, are based on the use of the federal government’s limited resources and include “law enforcement priorities set by the Attorney General,” the “seriousness” of the alleged crimes, the “deterrent effect of criminal prosecution,” and “the cumulative impact of particular crimes on the community.” Although the Sessions Memorandum emphasizes that cannabis is a federally illegal Schedule I controlled substance, it does not otherwise instruct U.S. Attorneys to consider the prosecution of cannabis-related offenses a DOJ priority, and in practice, most U.S. Attorneys have not changed their prosecutorial approach to date. However, due to the lack of specific direction in the Sessions Memorandum as to the priority federal prosecutors should ascribe to such cannabis activities, there can be no assurance that the federal government will not seek to prosecute cases involving cannabis businesses that are otherwise compliant with state law.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">William Barr served as United States Attorney General from February 14, 2019 to December 23, 2020. The DOJ under Mr. Barr did not take a formal position on federal enforcement of laws relating to cannabis. On March 11, 2021, United States President Biden’s nominee, Merrick Garland was sworn in as the U.S. Attorney General. During his campaign, President Biden stated a policy goal to decriminalize possession of cannabis at the federal level, but he has not publicly supported the full legalization of cannabis. It is unclear what impact, if any, the new administration will have on U.S. federal government enforcement policy on cannabis. Nonetheless, there is no guarantee that the position of the Department of Justice will not change.</p>
CY2014Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.625 pure
CY2018Q1 us-gaap Subsidiary Or Equity Method Investee Cumulative Percentage Ownership After All Transactions
SubsidiaryOrEquityMethodInvesteeCumulativePercentageOwnershipAfterAllTransactions
0.10 pure
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2498706 usd
CY2021Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
3000000 usd
CY2022 us-gaap Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
2740820 usd
CY2021 us-gaap Asset Impairment Charges
AssetImpairmentCharges
2498706 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-95079817 usd
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Use of Estimates</i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Reclassification</i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Certain amounts in the prior period have been reclassified to conform to the current period presentation.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2551859 usd
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1665263 usd
CY2022 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
79847 usd
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
15798 usd
CY2022 us-gaap Advertising Expense
AdvertisingExpense
1453727 usd
CY2021 us-gaap Advertising Expense
AdvertisingExpense
1237326 usd
CY2022 us-gaap Property Plant And Equipment Estimated Useful Lives
PropertyPlantAndEquipmentEstimatedUsefulLives
Term of lease
CY2022Q2 us-gaap Goodwill
Goodwill
557896 usd
CY2021Q2 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
3000000 usd
CY2022 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-97200 usd
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Concentrations of Credit Risk</i></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company maintains its cash in bank deposit accounts and other accounts, the balances of which at times may be uninsured or exceed federally insured limits. From time to time, some of the Company’s funds are also held by escrow agents; these funds may not be federally insured. The Company continually monitors its banking relationships and consequently has not experienced any losses in such accounts.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17361 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37122 usd
CY2022 us-gaap Revenues
Revenues
22662895 usd
CY2021 us-gaap Revenues
Revenues
19292087 usd
CY2022 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-112139 usd
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
75306426 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
129623809 shares
CY2021Q2 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
250069 usd
CY2022Q2 us-gaap Other Receivables
OtherReceivables
0 usd
CY2021Q2 us-gaap Other Receivables
OtherReceivables
10000 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
295869 usd
CY2021Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
262313 usd
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
25185003 usd
CY2018Q4 us-gaap Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
5000000 usd
CY2018Q4 clsh Note Receivable Interest Rate Stated Percentage
NoteReceivableInterestRateStatedPercentage
0.06 pure
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
618227 usd
CY2021Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
684935 usd
CY2022Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
297563 usd
CY2021Q2 us-gaap Inventory Raw Materials
InventoryRawMaterials
344085 usd
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3120039 usd
CY2021Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
883967 usd
CY2022Q2 us-gaap Inventory Net
InventoryNet
3417602 usd
CY2021Q2 us-gaap Inventory Net
InventoryNet
1228052 usd
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2073449 usd
CY2021Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1434614 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4342434 usd
CY2021Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3475668 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1104806 usd
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
269437 usd
CY2022Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
2016 usd
CY2021Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
2244 usd
CY2022Q2 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
293853 usd
CY2022 us-gaap Depreciation
Depreciation
638835 usd
CY2021 us-gaap Depreciation
Depreciation
569278 usd
CY2020 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
28511 usd
CY2021 us-gaap Other Nonoperating Gains Losses
OtherNonoperatingGainsLosses
14899 usd
CY2022Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P9Y
CY2022Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
221469 usd
CY2019Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4112876 usd
CY2022Q2 us-gaap Property Subject To Or Available For Operating Lease Accumulated Depreciation
PropertySubjectToOrAvailableForOperatingLeaseAccumulatedDepreciation
1958359 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2154517 usd
CY2020Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
14970 usd
CY2021 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
250000 shares
CY2021 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
215500 usd
CY2021Q2 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
150000 shares
CY2019Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
4069476 usd
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-1866069 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2203407 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2203407 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2203407 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
309597 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1893810 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
493327 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
502461 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
515988 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
451671 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
227053 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
741756 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2932256 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
728849 usd
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2203407 usd
CY2022Q2 clsh Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
1663593 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
473308 usd
CY2022Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1190285 usd
CY2021Q2 clsh Intangible Assets Gross Including Goodwill
IntangibleAssetsGrossIncludingGoodwill
1663593 usd
CY2021Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
358403 usd
CY2021Q2 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
1305190 usd
CY2022 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
114905 usd
CY2021 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
116014 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
28500 usd
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
28500 usd
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6105679 usd
CY2018Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.8
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
114896 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
114896 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
114896 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
114896 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
114854 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
615847 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1190285 usd
CY2022Q2 us-gaap Goodwill
Goodwill
557896 usd
CY2021Q2 us-gaap Goodwill
Goodwill
557896 usd
CY2022Q2 us-gaap Security Deposit
SecurityDeposit
229500 usd
CY2021Q2 us-gaap Security Deposit
SecurityDeposit
167455 usd
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
229500 usd
CY2021Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
167455 usd
CY2021Q1 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.3
CY2018Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
8408400 shares
CY2021Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
22516374 shares
CY2021Q1 clsh Warrant Description
WarrantDescription
each warrant issuable pursuant to conversion of the Canaccord Debentures is exercisable for one share of the Company’s common stock at a price equal to $0.40 per share until March 31, 2024.
CY2022Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1414074 usd
CY2021Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
771843 usd
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
323254 usd
CY2021Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
279721 usd
CY2022Q2 us-gaap Other Deferred Credits Current
OtherDeferredCreditsCurrent
580570 usd
CY2021Q2 us-gaap Other Deferred Credits Current
OtherDeferredCreditsCurrent
557061 usd
CY2022Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
2317898 usd
CY2021Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1608625 usd
CY2022 us-gaap Proceeds From Loans
ProceedsFromLoans
2322875 usd
CY2022 us-gaap Repayments Of Debt
RepaymentsOfDebt
1393966 usd
CY2022Q2 us-gaap Debt Instrument Fee Amount
DebtInstrumentFeeAmount
84164 usd
CY2022Q2 us-gaap Loans Payable
LoansPayable
1013073 usd
CY2022 us-gaap Debt Instrument Term
DebtInstrumentTerm
P30D
CY2022 clsh Discount Fee
DiscountFee
0.03 pure
CY2022 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
277017 usd
CY2021 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 usd
CY2021Q2 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
6229672 usd
CY2021Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.8
CY2021Q2 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.3
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
3893545 shares
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
19448821 usd
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
1250000 usd
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
1250000 usd
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
375000 usd
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
375000 usd
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
1125000 usd
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
23823821 usd
CY2022 clsh Debenture Offering Maximum
DebentureOfferingMaximum
5500000 usd
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.4125
CY2022 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2500000 usd
CY2022 clsh Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
3030304 shares
CY2021Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2022Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
12204928 usd
CY2021Q2 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
7457218 usd
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P18M
CY2021Q4 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
20 acre
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
359900 usd
CY2022Q1 us-gaap Lessor Direct Financing Lease Variable Lease Payment Terms And Conditions
LessorDirectFinancingLeaseVariableLeasePaymentTermsAndConditions
forty-eight monthly installments of $10,173
CY2022Q2 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.1589 pure
CY2022 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
10907 usd
CY2022 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
9439 usd
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
348993 usd
CY2021Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
0 usd
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
348993 usd
CY2021Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
0 usd
CY2022Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
71813 usd
CY2021Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0 usd
CY2022Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
277180 usd
CY2021Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
0 usd
CY2022Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
348993 usd
CY2021Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
0 usd
CY2021Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
10382785 shares
CY2021Q2 clsh Warrant Description
WarrantDescription
each warrant issuable pursuant to conversion of such debentures is exercisable for one share of the Company’s common stock at a price equal to 137.5% of the conversion price (presently $0.4125 per share) until July 14, 2024
CY2022Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
71813 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
84064 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
98405 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
94711 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due Year Five
FinanceLeaseLiabilityPaymentsDueYearFive
0 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due After Year Five
FinanceLeaseLiabilityPaymentsDueAfterYearFive
0 usd
CY2022Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
348993 usd
CY2021Q4 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P9Y
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
10000 usd
CY2022 us-gaap Loss Contingency Disclosures
LossContingencyDisclosures
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>NOTE 19</b> –<b> CONTINGENT LIABILITY</b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The terms of the Company’s acquisition of Alternative Solutions, included a payment of $1,000,000 contingent upon the Oasis LLCs achieving certain revenue targets. (see note 3). The fair value of this contingent consideration at the time of the Acquisition Agreement was $678,111 as determined by the Company’s outside valuation consultants. Management reviewed the value of the contingent consideration, and concluded that, due to the increased revenue of Alternative Solutions, the fair value of this contingent liability was $1,000,000 at May 31, 2019. The Company recorded a charge to operations in the amount of $321,889 during the year ended May 31, 2019.</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"> </p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The full amount of the bonus payment was earned, and on May 27, 2020, the Company made a payment in the amount of $850,000 to the sellers. The Company deposited the balance due to sellers of $150,000 with an escrow agent to hold pending the outcome of a tax audit. During the year ended May 31, 2020, the State of Nevada notified the Oasis LLCs that it would be conducting a tax audit for periods both before and after the closing of the sale to CLS. The tax audit was completed and the Company received a deficiency notice dated January 29, 2021. The Company paid the tax due and on February 16, 2021, $41,805 of the escrowed amount was released to the Company, $106,195 was released to sellers and the balance of $2,000 was remitted to the escrow agent as payment of its fees.</p>
CY2019Q2 us-gaap Business Combination Liabilities Arising From Contingencies Amount Recognized
BusinessCombinationLiabilitiesArisingFromContingenciesAmountRecognized
1000000 usd
CY2018Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
678111 usd
CY2019 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
321889 usd
CY2020Q2 us-gaap Payment For Contingent Consideration Liability Operating Activities
PaymentForContingentConsiderationLiabilityOperatingActivities
850000 usd
CY2021Q1 us-gaap Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1
BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
106195 usd
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000 shares
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
128208082 shares
CY2021Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
127221416 shares
CY2021Q3 us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
936666 shares
CY2021Q3 clsh Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
468333 shares
CY2021Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.1
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.4
CY2021Q3 us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
281000 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
50000 shares
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
4390 usd
CY2022Q1 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
50000 shares
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
4390 usd
CY2022 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
50000 shares
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
4390 usd
CY2022 clsh Number Of Shares To Be Issued
NumberOfSharesToBeIssued
50000 shares
CY2020Q4 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
50000 shares
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
2500000 usd
CY2022Q1 clsh Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
3030304 shares
CY2022Q1 clsh Warrant Description
WarrantDescription
Each warrant allows the holder to purchase one share of the Company’s common stock at an exercise price of $0.4125 per share for three years after its date of issuance
CY2022Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.4125
CY2022Q1 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6451339 shares
CY2022 clsh Warrants Outstanding Weighted Average Remaining Contractual Term
WarrantsOutstandingWeightedAverageRemainingContractualTerm
P1Y5M12D
CY2022 clsh Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding
0.5
CY2022 clsh Class Of Warrant Or Rights Exercisable
ClassOfWarrantOrRightsExercisable
6451339 shares
CY2022 clsh Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercisable
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercisable
0.5
CY2020Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
54835145 shares
CY2020Q2 clsh Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding
0.53
CY2021 clsh Granted Number Of Shares
GrantedNumberOfShares
0 shares
CY2021 clsh Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsGranted
1.1
CY2021 clsh Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
0 shares
CY2021 clsh Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercised
0
CY2021 clsh Class Of Warrant Or Rights Cancelled Expired
ClassOfWarrantOrRightsCancelledExpired
-837500 shares
CY2021 clsh Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Cancelled Expired
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsCancelledExpired
0.75
CY2021Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
53997645 shares
CY2021 clsh Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding
0.53
CY2022 clsh Granted Number Of Shares
GrantedNumberOfShares
3030304 shares
CY2022 clsh Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsGranted
0.41
CY2022 clsh Class Of Warrant Or Rights Exercised
ClassOfWarrantOrRightsExercised
0 shares
CY2022 clsh Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsExercised
0
CY2022 clsh Class Of Warrant Or Rights Cancelled Expired
ClassOfWarrantOrRightsCancelledExpired
-50576610 shares
CY2022 clsh Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Cancelled Expired
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsCancelledExpired
0.52
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6451339 shares
CY2022 clsh Class Of Warrant Or Rights Weighted Average Exercise Price Of Warrants Or Rights Outstanding
ClassOfWarrantOrRightsWeightedAverageExercisePriceOfWarrantsOrRightsOutstanding
0.5
CY2018Q1 clsh Class Of Warrant Or Rights Granted
ClassOfWarrantOrRightsGranted
205238 shares
CY2018Q2 clsh Warrants Issued Price Per Warrant
WarrantsIssuedPricePerWarrant
0.45
CY2022Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2021Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0 usd
CY2022 us-gaap Stock Issued During Period Shares Share Based Compensation Gross
StockIssuedDuringPeriodSharesShareBasedCompensationGross
100000 shares
CY2022 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
8780 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
50000 shares
CY2022 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
50000 shares
CY2022 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
4390 usd
CY2022 us-gaap Revenues
Revenues
22662895 usd
CY2022 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-12941530 usd
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
9721365 usd
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.21 pure
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2041487 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
2563035 usd
CY2021Q2 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
1566016 usd
CY2022Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
2563035 usd
CY2021Q2 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
1566016 usd
CY2022Q2 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 usd
CY2021Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P3Y
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001522222

Files In Submission

Name View Source Status
0001185185-22-001017-index-headers.html Edgar Link pending
0001185185-22-001017-index.html Edgar Link pending
0001185185-22-001017.txt Edgar Link pending
0001185185-22-001017-xbrl.zip Edgar Link pending
cls20220531_10k.htm Edgar Link pending
cls20220531_10kimg001.jpg Edgar Link pending
clsh-20220531.xsd Edgar Link pending
ex_413946.htm Edgar Link pending
ex_413947.htm Edgar Link pending
ex_413948.htm Edgar Link pending
ex_416534.htm Edgar Link pending
ex_416541.htm Edgar Link pending
ex_416554.htm Edgar Link pending
ex_416555.htm Edgar Link pending
ex_416601.htm Edgar Link pending
ex_416601img001.jpg Edgar Link pending
ex_416601img002.jpg Edgar Link pending
ex_416601img003.jpg Edgar Link pending
ex_416601img004.jpg Edgar Link pending
ex_416601img005.jpg Edgar Link pending
ex_416601img006.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mkcpa_logo1.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
clsh-20220531_def.xml Edgar Link unprocessable
clsh-20220531_lab.xml Edgar Link unprocessable
clsh-20220531_pre.xml Edgar Link unprocessable
cls20220531_10k_htm.xml Edgar Link completed
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R87.htm Edgar Link pending
R88.htm Edgar Link pending
R89.htm Edgar Link pending
R9.htm Edgar Link pending
R90.htm Edgar Link pending
R91.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
clsh-20220531_cal.xml Edgar Link unprocessable